At week 12 , patients achieving 75 % or more improvement from baseline Psoriasis Area and Severity Index score ( PASI 75 ) were rerandomized to 2 dose levels of secukinumab retreatment as needed ( n = 217 , 300 mg ; n = 206 , 150 mg ) or fixed interval ( n = 217 ; n = 203 ) .